Thursday 16 October, 2025
Introduction: CD3 T-cell Bispecific (TCB) antibodies, which redirect T-cells towards tumor cells showed promising results in the clinic. However, Cytokine…
Read morePoster: Drug/Disease Modelling - Oncology
Translational PK/PD modeling to support First-In-Human clinical trial of a MAT2A inhibitor
Thursday 16 October, 2025
Objectives: The deletion of metabolic gene methylthioadenosine phosphorylase (MTAP) occurs, globally, in 15% of human cancers [1] with unmet needs….
Read morePhysiologically-based pharmacokinetic (PBPK) modelling for predicting drug-disease interactions: Suppression of CYP3A4 by interleukin-6 in cancer populations
Thursday 16 October, 2025
Introduction: Interleukin-6 (IL-6) is one of the major proinflammatory cytokines that is elevated in several cancer sub-types [1]. Studies have…
Read moreMechanistic modelling of CAR T-cell therapy for multiple myeloma to assess multi-antigen targeting and identify factors associated with response.
Thursday 16 October, 2025
Introduction: Despite promising outcomes in CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM), nearly all patients eventually relapse. Resistance and…
Read morePopulation Pharmacokinetic Modeling and Covariate Analysis of Lenalidomide in Renally Impaired Patients with Multiple Myeloma
Thursday 16 October, 2025
Objectives Chronic kidney disease (CKD) is a common complication in multiple myeloma (MM) due to immunoglobulin-induced kidney damage. Lenalidomide, a…
Read moreInvestigating the Impact of the Binding Site Barrier on Antibodies: A Comparative Study of ODE and PDE Models
Thursday 16 October, 2025
Introduction: Antibody Drug Conjugates (ADCs) represent a novel therapeutic modality which are currently mainly used for the treatment of cancer….
Read moreCan the PK drivers of anti-tumour response be xenograft specific
Thursday 16 October, 2025
Objectives In oncology, the use of in-vitro to in-vivo correlations (IVIVC) is prevalent, linking in-vitro parameters like IC50 to in-vivo…
Read morePopulation pharmacokinetic (PPK) modeling analyses of tovorafenib in patients with RAF-altered, relapsed/refractory (r/r) pediatric low-grade glioma (pLGG), advanced solid tumors, and healthy adults
Thursday 16 October, 2025
Objectives: Genetic alterations and dysregulation of the mitogen-activated protein kinase (MAPK) pathway have been found in many different types of…
Read moreAnalysis of Itacitinib effect on the biomarkers of inflammatory response in subjects with hematological malignancies treated with CAR-T therapy
Thursday 16 October, 2025
Introduction: Itacitinib (INCB039110), a novel, selective oral Janus kinase 1 (JAK1) inhibitor, was evaluated as monotherapy in a phase 2…
Read moreAn Integrative Pharmacometric Approach Supports the Dose Selection Proposal of Englumafusp Alfa, a New Molecular Entity with No Single Agent Activity Developed in Combination
Thursday 16 October, 2025
Background: Englumafusp alfa (ENGLU) is a CD19-4-1BBL antibody-like fusion protein targeting CD19 on B cells and 4-1BB on immune cells…
Read more